Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
2021-000387-30Phase 3Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deuruxolitinib in alopecia areata (3 arms), sponsored by Concert Pharmaceuticals. Primary endpoint: SALT score ≤20 at Week 24. Started Apr 2021; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2021-000387-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000387-30.